Selling Peptides to Clinics: Vet the Buyer and Use

How should a research peptide store handle selling peptides to clinics?

Treat selling peptides to clinics as a conditional screening decision. Before quoting, verify the buyer’s business identity, authorized contact, and documented research purpose. Do not fill requests tied to patients or compounding from research use only inventory; send uncertain cases for qualified review. FDA has found human-use intent despite RUO labeling. [1]

Your immediate job is to decide what the inquiry actually concerns. A clinic name on an email does not tell you whether the requested material is for a separate nonclinical research project, an unexplained destination, or patient care. Build your response around the proposed use and the transaction you can verify.

Use the worksheets below as recommended internal controls for your US research store. They help you organize an accept, pause, or decline decision, but they do not establish that a particular product, buyer, or sale meets applicable legal requirements. Keep those questions with qualified counsel.

Key Facts

• FDA said website evidence established human-drug intended use despite research-use-only statements in its Summit Research Peptides warning letter. You should therefore examine the surrounding claims and proposed use, not rely on the label alone. [1]
• FDA describes section 503A as covering specified human drug compounding by licensed pharmacists within state-licensed pharmacies or federal facilities, or by licensed physicians, outside the registered outsourcing facility context. Keep that role separate from your research-store intake. [2]
• FDA describes section 503B as applying to human drug compounding within an outsourcing facility. That classification does not turn a research-store buyer screen into permission to supply compounding. [3]
• FDA identifies a valid prescription for an individually identified patient as a condition under section 503A, while explaining that a section 503B outsourcing facility may or may not obtain individual patient prescriptions. You cannot use the presence or absence of a prescription as a universal buyer test. [4][5]
• FDA's September 18, 2026 letter to Empower Pharmacy describes investigators' evidence that products produced by that pharmacy failed to meet section 503A conditions. Keep this as a case-specific agency allegation, not a conclusion about other pharmacies. [6][7]
• The Mississippi boards' posted statement says healthcare providers there must not compound, administer, or dispense non-FDA-approved or research-grade peptides to patients. Its publication and effective dates are unknown in the supplied agency evidence; its state-specific scope matters. [8]

TL;DR

Before preparing a quote, establish who is asking, what nonclinical project they describe, and where the material would go. Compare those answers across the project narrative, purchasing contact, payer, and receiving team. Pause unresolved contradictions, decline patient care or compounding requests from your RUO inventory, and send disputed classifications for qualified review. Use the resulting decision only for the reviewed inquiry, with fresh screening when its facts change.

Separate research procurement from clinical supply

Classify the requested activity before you classify the customer. Keep genuine nonclinical research procurement separate from patient care and compounding, even when the same organization has interests in more than one activity.

Start your buyer-use policy with the boundary you intend to operate: you assess documented nonclinical research inquiries, and you do not fulfill patient care or compounding requests from research-use-only inventory. Make this a store operating rule that your team can apply to a request. Do not describe the rule as a substitute for product-specific or jurisdiction-specific legal review.

Your first output should be a role map. Use it to choose the next question, rather than to rank how credible a buyer sounds. A professional title can explain someone's organizational role while leaving the intended use unanswered. Equally, a purchasing employee may be able to explain a separate research project without being the person who can authorize the purchase.

In a hypothetical inquiry, a clinic's administrator describes an internal nonclinical analytical project and identifies a separate project owner. Your next question concerns that project and its destination. In another hypothetical inquiry, the administrator asks for material for the clinic's patient service. Your next action is to decline that use from your RUO inventory. The organizational name is unchanged; the proposed activity changes your response.

Do not collapse the pharmacy and prescriber rows into a generic medical-buyer category. FDA's descriptions of sections 503A and 503B concern different compounding contexts, and its discussion of patient prescriptions shows why a single credential question cannot replace the distinction. [2][3][4][5] Your worksheet should preserve the claimed role in the buyer's own words, alongside the particular activity they describe.

Test your policy with a handoff question: could someone who did not receive the original email explain why the inquiry belongs in the research queue? If the explanation is only that the buyer is a clinic, you have identified an organization, not a qualifying research purpose. Ask the missing use question before you begin commercial discussions.

For the labeling issue, use research use only and what it actually means as a companion topic. FDA's Summit letter supplies the relevant example here: the agency relied on website evidence despite RUO statements. [1] Your role map should lead you toward examining that surrounding context, not toward finding a more reassuring label.

Verify the organization and authorized buyer

Verify the business identity and the purchasing contact separately so you know both who the proposed customer is and who can speak for it. Treat the intake fields below as recommended controls, not as a federally prescribed form.

Build your intake around answers you can compare. Ask for the entity that would appear on the quote, its business location, the organizational website, and the person requesting the purchase. Then ask how that person's role connects to purchasing and to the stated project. Keep the questions ordinary and specific; you need a business explanation, not a collection of impressive titles.

For a hypothetical incomplete intake, imagine an email signed “Purchasing” that names a clinic brand but omits the legal entity and project contact. The email includes a public website and asks you to quote immediately. You can acknowledge the inquiry, but you should mark the identity task incomplete. A website reference does not answer who will contract with you or who owns the stated project.

Your reply could say: “Please confirm the legal entity requesting the quote, your purchasing role, and the project contact who can explain the proposed nonclinical research use.” This asks for the missing business facts without suggesting how to construct an acceptable research story. Do not fill blank fields yourself by choosing whichever entity name appears most prominently on the website.

Use a callback to resolve a particular question. For example, in a hypothetical inquiry, the project contact confirms that the requester works with the organization but says a different department authorizes purchases. Your identity check has established affiliation while leaving purchasing authority unresolved. Send the authorization question to that department instead of treating affiliation as permission to proceed.

Separate a clerical correction from a material change. If a hypothetical contact corrects a misspelled entity name and the other details remain consistent, update the field and preserve the explanation. If the proposed contracting entity changes to an unrelated organization, reopen the entity review and ask about the relationship. Neither situation needs an accusation; each needs the right question.

Assign the identity task to the person managing intake, and define its handoff: the commercial reviewer receives a named entity, a confirmed organizational contact route, and an explanation of the purchaser's role. That reviewer still needs the separate intended-use assessment. Avoid a single “verified customer” badge that hides which checks were completed and which remain open.

Use research-buyer screening to connect this intake with your broader store workflow. Keep the clinic inquiry in the same factual discipline: a recognizable organization deserves clear questions, not an exemption from them. The guide Can You Sell Peptides on TikTok Shop? Commerce Policy Versus Ad Policy covers this in more detail.

Record the intended research use before quoting

Ask for a specific nonclinical project purpose before you quote, and preserve the buyer's own explanation of the expected end user and downstream use. A checked research box should begin your inquiry, not finish it.

Your intended-use questionnaire should help you understand the work without soliciting patient information. Ask about the project, its setting, the person responsible for it, and whether the material would move elsewhere. You do not need a clinical history or any personal health details to decide that a patient-use request falls outside your RUO inventory policy.

Use questions that allow a factual answer. “Can you confirm this is research?” invites a label. “What nonclinical project would this material support?” asks for the activity behind the label. If the buyer cannot describe that activity, preserve the gap rather than turning a generic assurance into a detailed purpose statement on their behalf.

In a hypothetical project description, “our laboratory is comparing analytical methods for a nonclinical project” gives you a starting point, but not a completed screen. Ask who owns the project, where it occurs, and who receives the material. You are checking the procurement context, not evaluating the scientific merits or designing the experimental procedure.

In another hypothetical description, the buyer says “research” but refers to the clinic's patient program when explaining why the order is urgent. Do not rewrite the statement to remove the conflict. Stop the quote process, preserve the conflicting explanations, and apply your patient-use boundary. FDA's Summit letter demonstrates why surrounding website evidence can matter despite a research label. [1]

Compare the response with the claims visible in the inquiry and the business context you have reviewed. If an organizational website describes clinical services, ask how the proposed project is separate; the website alone does not establish the use of this particular order. If the buyer's own request explicitly links the material to patient care, do not treat a later generic RUO assurance as resolving that link.

Build a quote handoff that states the purpose without changing it. Your internal summary might identify the described project, project owner, research setting, expected user, and open transfer question. If the transfer question remains unanswered, the summary should leave the inquiry paused. A quotation should not become the mechanism for obtaining facts you needed before deciding whether to offer one.

Keep the scope of any response clear. If the buyer asks you to recommend material for a human purpose, decline that part of the request rather than providing a suggestion and attaching a disclaimer. For a broader discussion of how claims can affect intended-use analysis, see FDA warning letters and peptide marketing. The source-backed lesson for this worksheet remains the agency's Summit finding, not a promise that a completed questionnaire resolves the issue. [1]

Evaluate the evidence behind the stated project

Compare independent pieces of project evidence and identify exactly what each supports. Use a proportional review that resolves material gaps without treating a professional credential, letterhead, or signed statement as conclusive.

Your work product here is an evidence sufficiency matrix. It should distinguish between an answer being supplied and that answer being corroborated. A detailed narrative may explain the proposed activity while leaving the project owner's connection to the organization uncertain. A callback may confirm the contact while leaving the downstream destination unclear. Keep those outcomes separate.

Choose a question by identifying the missing link. In a hypothetical file, the project narrative and order match, but the project contact cannot be reached through the organization. Request a verifiable organizational connection. Asking for more pages about the project would not solve the contact problem. Your next action should address the weak link, not increase the size of the file.

In a different hypothetical file, the contact is readily confirmed but gives an explanation of the material's destination that conflicts with the purchasing email. Ask the purchaser and project owner to reconcile that destination. Keep both original answers available. Do not select the more convenient answer merely because it allows the commercial conversation to continue.

Use document checks that a colleague can repeat. Confirm that a supplied document refers to the entity, project, and contact under review. Look for an internal contradiction such as a different project name or an unexplained receiving organization. Ask about that discrepancy directly. Describe the observation as a mismatch until you have evidence supporting a stronger conclusion.

Do not request unrelated information simply to make the review feel more rigorous. If you can resolve the project-owner relationship through an organizational callback, an unrelated financial document does not answer the same question. If an answer would require disclosing patient information, stop and reformulate the request around organizational purpose; patient data is not your missing research credential.

Define an evidence endpoint for each open issue. You might close a contact gap when the organization confirms the person's project role, while leaving an unexplained transfer gap open. Your reviewer should be able to point to the particular answer that changed the issue's status. Avoid an overall confidence score that lets strong identity evidence cancel a direct patient-use statement.

Keep buyer evidence separate from product and supplier evidence. A supplier document can belong in your purchasing review without establishing who will use an outbound order. Use your peptide supplier vetting checklist for that separate task. The evidence matrix in this section should end with a clear assessment of the proposed buyer and project, not borrow reassurance from a different part of the business.

Trace who purchases, receives and uses the material

Map the purchaser, payer, delivery location, receiving team, and expected end user before treating an inquiry as ready for a commercial decision. Resolve unexplained changes between those roles rather than assuming that the name on the order describes the whole transaction.

Your transaction-chain worksheet should follow the material's proposed path. Ask the buyer to explain the business relationship wherever the named parties differ. You are not establishing wrongdoing from a mismatch. You are deciding whether you understand the inquiry well enough to assess it under your nonclinical research policy.

Consider a hypothetical order in which the purchasing entity describes a nonclinical research project, while the delivery address belongs to a different business. Pause the request and ask why that business would receive the material. If the buyer explains that it is the research site, seek confirmation of its connection to the named project. If the explanation instead identifies a patient-care destination, decline that use from your RUO inventory.

The useful distinction is between an explained relationship and an unexplained substitution. In a hypothetical centralized purchasing arrangement, the payer may differ from the research team. You can evaluate the arrangement by asking who authorizes payment and how the payer connects to the purchasing entity. The different name alone does not establish a problem, and the explanation alone does not settle intended use.

Use the worksheet to catch a change that arrives after intake. Suppose, hypothetically, that the buyer asks you to replace the reviewed destination with another site while leaving the project narrative untouched. Reopen the destination and receiver questions before progressing. Do not allow a delivery edit to inherit a decision made about a different chain.

Make ownership explicit at the handoff to fulfillment. Your commercial reviewer should identify the reviewed entity, destination, and receiving team. Your fulfillment contact should compare the actual order instructions with those entries and return material mismatches for review. Give that contact permission to hold the handoff when the information differs, rather than requiring them to interpret the buyer's intent.

Keep payment checks within their proper role. A payment confirmation tells your team something about the transaction's payment state; it should not replace your understanding of the proposed research use. Likewise, a familiar shipping address should not settle who will use a new order. Your review should carry each answer to the task it actually informs.

End this worksheet with a chain statement in ordinary language: the named entity purchases for the named project, the identified business pays, and the stated research team receives at the reviewed site. Add any proposed downstream recipient explicitly. If you cannot complete that sentence without guessing, keep the missing relationship open and ask the relevant party to explain it.

Escalate patient care and compounding signals

Decline requests for patient care or compounding from your research-use-only inventory, and send unresolved classifications to qualified review. Use the source examples to frame the questions for that review, not to construct a route for filling an unsuitable request.

Separate an evidence gap from a direct statement of excluded use. An absent project contact may justify a pause while you request clarification. An explicit request for patient supply calls for a clear boundary response. If you place both situations in a generic “needs documents” queue, you risk implying that extra paperwork can resolve a use your store does not serve.

FDA's distinction between compounding contexts matters because a buyer may use a category name as if it answered all your questions. The agency describes section 503A in terms of specified licensed pharmacist or physician compounding, and section 503B in terms of compounding within an outsourcing facility. [2][3] Preserve those distinctions in your escalation note. Do not relabel a compounding request as research because the buyer holds a professional role.

The patient-prescription distinction is another reason to avoid shortcuts. FDA identifies valid prescriptions for individually identified patients as a condition under section 503A, while stating that an outsourcing facility under section 503B may or may not obtain such prescriptions. [4][5] Therefore, the absence of a prescription in an inquiry does not establish a nonclinical purpose. Do not ask the buyer to send patient prescriptions as a way of qualifying for your research-store inventory.

Use the Empower example narrowly. In its September 18, 2026 warning letter, FDA said investigators collected evidence indicating that products produced by Empower Pharmacy failed to meet section 503A conditions. [6][7] This is the agency's case-specific allegation in that letter. It does not establish the status of another pharmacy, resolve an individual buyer's inquiry, or authorize your store to supply compounding material.

Use the Mississippi example with the same discipline about scope. The boards' posted statement addresses providers there and says they must not compound, administer, or dispense non-FDA-approved or research-grade peptides to patients. [8] The publication and effective dates are unknown in the source evidence used here. Do not assign a date to the statement or present it as a uniform rule for every state.

For an escalation handoff, give counsel the original request, the buyer's claimed role, the stated purpose, the unresolved facts, and the relevant source link. Ask a bounded question about those facts. Avoid asking for a general approval letter that you intend to reuse for unrelated buyers or later uses. Keep the commercial request paused while its classification remains unresolved.

Use state business licensing questions and whether you need a license to sell peptides to separate broader business questions from this inquiry. Your buyer screen does not answer them. If your question concerns operating a clinical business, opening a peptide clinic is a separate subject; it does not change your research inventory boundary.

Apply an accept, pause or decline decision rule

Use the same rule for every inquiry: consider acceptance only for a coherent, documented nonclinical request within your reviewed business scope; pause unresolved material gaps; decline patient care or compounding requests from RUO inventory. Treat acceptance as an internal screening outcome, never as a legal determination.

Order the rule so that a disqualifying use cannot be offset by stronger business credentials. First ask whether the buyer explicitly proposes patient care or compounding. Then ask whether the nonclinical purpose, organizational identity, and transaction chain are sufficiently understood. Finally, identify any product-specific or jurisdiction-specific questions that require qualified review before a commercial decision.

This is a decision sequence, not a points system. A recognizable entity, a responsive contact, and a complete address should not outweigh a stated patient purpose. FDA's Summit finding illustrates why a research label can conflict with surrounding evidence of human-drug intended use. [1] Your operating rule should respond to that contradiction rather than average it away.

The following scenarios are hypothetical operating examples. They illustrate how to use the same inputs; they do not establish that any real buyer or transaction satisfies applicable law.

For the hypothetical research inquiry, write a narrow decision. Identify the project and destination you reviewed, and say what the acceptance covers. Do not approve every future purchase by the organization. If a separate question about the product or business scope remains open, keep the commercial decision paused even though the buyer's explanation is coherent.

Your response to that hypothetical buyer can say: “Your inquiry has completed our internal research-buyer screen for the project and delivery details reviewed. Any quote would relate to those details, and changes would need review.” This describes a process outcome without claiming that a particular sale has legal clearance. Do not add language that suggests suitability for any human purpose.

For the hypothetical unclear inquiry, identify the precise missing facts: the project owner, the nonclinical activity, and the connection to the delivery site. Send a focused request instead of a generic rejection. Your response can say: “We cannot prepare a quote while the project purpose and receiving-site relationship remain unclear. Please identify the responsible project contact and explain those details.”

For the hypothetical excluded-use inquiry, avoid an invitation to rename the project. Your response can say: “We do not fulfill patient-care or compounding requests from research-use-only inventory.” If the buyer disputes the classification, preserve the original request and route the dispute for qualified review. Do not provide alternate wording, another ordering channel, or a substitute identity that would allow the same request to appear different.

Test consistency by switching the buyer's presentation while keeping the facts unchanged. If a polished website changes your decision on an otherwise unresolved hypothetical request, ask which missing fact the website actually resolved. If it resolved none, the outcome should remain paused. Your rule should respond to evidence about the inquiry, not the commercial appeal of the account.

Preserve a reviewable decision record

Record the evidence and reasoning that produced the screening outcome so another authorized reviewer can reconstruct it. Keep the record specific to the inquiry, with unresolved facts visible and corrections attached to the original decision.

Your decision log should be useful after the conversation has moved on. A label such as “approved clinic” loses the purpose, destination, and limits that mattered. Replace it with a record that connects the buyer's statements, your checks, the reviewer, and the exact scope of the outcome. These are recommended internal practices, not a claim about a mandatory federal record format.

Keep observation and interpretation separate within the rationale. In a hypothetical log, “the project contact confirmed the receiving team's involvement” is an observation about a contact result. “The receiving relationship is sufficiently explained for our internal screen” is your assessment. Writing both allows another reviewer to examine whether the assessment follows from the observation.

Use the same distinction for unresolved issues. “The buyer did not answer the downstream transfer question” is more useful than “the buyer seems suspicious.” The former identifies a task you can reopen if new information arrives. The latter makes a personal judgment without naming the evidence that would change the decision. Keep your record focused on the inquiry's facts.

For a hypothetical correction, suppose the buyer explains that the original delivery entry was a clerical mistake and provides the intended research site. Attach the correction to the original entry, identify what changed, and send the destination question back through review. Do not silently replace the earlier address and leave the old decision looking as though it covered the corrected chain all along.

Give your reviewer a practical reconstruction test. Ask them to identify the reason for the outcome using only the file, then name the fact that would require reconsideration. If they must call the original salesperson to understand the decision, strengthen the missing link in the record. If they can identify both the rationale and the reopening condition, the handoff is usable.

Tie the reviewed inquiry to the actual order reference if it progresses. Where your internal process links orders and lots, use inventory lot tracking for that separate traceability task. Keep the link factual: which order and material the decision concerned. Do not let a lot reference become an endorsement of an unreviewed use.

Restrict the record to the business facts needed for the decision. Do not solicit or copy patient details into a research-buyer log. When a message introduces patient information, stop using it as qualification evidence and move the inquiry to the excluded-use response or qualified review as appropriate. Your completed work product should explain the decision without turning into a file about an individual's care.

Recheck accounts when facts or requests change

Reopen the relevant part of your screen when the buyer, purpose, or transaction chain changes. Keep prior acceptance attached to the facts reviewed instead of allowing it to become permanent account-wide permission.

Build your rescreen checklist around changes your team can recognize during ordinary work. A salesperson may notice a new project description, a fulfillment contact may notice a different delivery site, and a purchasing administrator may notice a different payer. Assign each person a clear return path so the change reaches the reviewer who owns the affected question.

Treat an ordering change as a question, not proof. In a hypothetical repeat inquiry, the requested amount differs from the earlier order. Ask how the changed request relates to the described project. Do not invent a universal quantity threshold or presume that a larger order reveals misuse. The relevant test is whether the explanation and transaction remain coherent within the scope you reviewed.

In a hypothetical destination change, the buyer wants the order sent to a site your earlier file does not mention. Reopen the site and receiver fields while retaining the existing identity evidence that remains applicable. This lets you review the changed relationship without pretending that every old answer became false or that the new address was already covered.

In a hypothetical repeat request that introduces patient-care language, the consequence is different. Apply your excluded-use boundary and stop treating the earlier nonclinical project screen as relevant permission. Preserve the changed statement and obtain qualified advice where classification is disputed. A prior relationship should not make a new intended-use conflict disappear.

Create a change handoff with a short description of the old fact, the new fact, and the affected decision. Your fulfillment contact should not have to interpret a full email history to know whether the current destination matches the reviewed one. Your reviewer should not have to guess why the order returned to the queue. Naming the changed field connects the operational interruption to the question that resolves it.

Use an account view to show the status of individual inquiries rather than a broad promise of eligibility. You might have a completed nonclinical inquiry alongside a different paused request from the same organization. Keep the reasons visible at the inquiry level. Do not allow a completed file to automatically release another order whose purpose or receiving chain remains unresolved.

Close the rescreen by identifying what the new decision supersedes. If the facts are clarified and the revised inquiry fits your internal scope after applicable review, attach the outcome to the revised details. If the use is excluded, retain the decline for that request. Your operational goal is a current, explainable decision for the actual inquiry in front of you.

What to do next

Build your next inquiry file in this order so each decision has the inputs it needs.

1. Write a buyer-use policy that separates nonclinical research inquiries from patient care and compounding requests.

2. Collect the legal entity, business location and authorized purchasing contact for each inquiry.

3. Ask for the specific project purpose and expected end user before preparing a quote.

4. Compare the project narrative with the material, quantity, payer, delivery site and receiving team.

5. Pause inconsistent requests and route patient-use, compounding or disputed classifications to qualified review.

6. Record the evidence reviewed, unresolved questions and decision rationale in an order log.

7. Recheck the account when the buyer, ship-to chain or intended use changes.

When should you book a peptide business fit call?

Book a peptide business fit call when you need to organize a consistent intake process for clinic inquiries to your research store. Bring a sample inquiry with personal details removed, your intended-use questionnaire, and your current decision log so you can discuss the workflow and its handoffs. The call is for business process fit, with no legal advice or approval promise.

Frequently Asked Questions

How can I legally sell peptides?

You need qualified review of the specific product, intended use, claims, and applicable requirements; this buyer-screening process cannot give you a blanket legality conclusion. Start by separating your proposed nonclinical research activity from patient care and compounding requests. FDA's Summit letter shows that RUO statements did not override the website evidence of human-drug intended use in that case. [1]

How do I sell peptides for research?

Start your inquiry process with the business identity, purchasing authority, specific nonclinical project, and expected end user. Compare those answers with the material requested and the proposed delivery chain before considering a quote. Keep unresolved classifications with qualified reviewers, and do not treat a completed questionnaire as authorization for patient use or compounding.

Is it legal to sell peptides online?

You cannot answer that for a particular store from the online sales channel alone. Ask counsel to review your products, claims, intended uses, and applicable rules against your actual business facts. Use the Summit warning letter as a scoped example of FDA examining website evidence despite research labeling, not as a universal decision about every online store. [1]

How do I become a peptide distributor?

Define whether your proposed business concerns nonclinical research distribution or a different regulated activity before planning buyer intake. Keep supplier review, buyer review, and licensing questions as separate workstreams with their own evidence. FDA's descriptions of sections 503A and 503B concern human drug compounding contexts; do not treat those categories as a distribution pathway for your RUO store. [2][3]

Are peptide clinics profitable?

You cannot infer clinic profitability from the sources used here, and a prospective account's commercial appeal should not change your buyer-use boundary. For a hypothetical screening-cost model, calculate your review cost as review hours multiplied by your assumed hourly cost, plus any separately assumed external review expense; this is a planning formula, not an earnings estimate. Use that model to understand your intake workload while continuing to decline patient-care and compounding requests from RUO inventory.

Sources

Use the numbered sources to check the specific agency statements cited above; repeated entries identify different retained claims from the same page.

1. U.S. Food and Drug Administration, Summit Research Peptides warning letter, accessed 2026-09-30.

2. U.S. Food and Drug Administration, FD&C Act Provisions That Apply to Human Drug Compounding, accessed 2026-09-30.

3. U.S. Food and Drug Administration, FD&C Act Provisions That Apply to Human Drug Compounding, accessed 2026-09-30.

4. U.S. Food and Drug Administration, Empower Clinic Services LLC dba Empower Pharmacy warning letter, accessed 2026-09-30.

5. U.S. Food and Drug Administration, FD&C Act Provisions That Apply to Human Drug Compounding, accessed 2026-09-30.

6. U.S. Food and Drug Administration, Empower Clinic Services LLC dba Empower Pharmacy warning letter, accessed 2026-09-30.

7. U.S. Food and Drug Administration, Empower Clinic Services LLC dba Empower Pharmacy warning letter, accessed 2026-09-30.

8. Mississippi State Board of Medical Licensure, Mississippi Board of Nursing, Mississippi Board of Pharmacy, Peptide Statement, accessed 2026-09-30. Publication and effective dates: UNKNOWN.

Educational and legal disclaimer

This article provides educational information only, not legal, regulatory, tax, banking, medical, product, import, platform, or payment advice. Use qualified advisers to evaluate your specific business facts and applicable requirements. Nothing here authorizes human use, patient supply, or compounding from research-use-only inventory, and the proposed screening controls do not establish the lawfulness of a product, buyer, or sale.